BioSpace News Archive

PharmaEssentia USA Corporation announced that it will host an Investor Day on Wednesday, November 30, 2022, 8:00 - 10:30 a.m.

The Alzheimer’s Drug Discovery Foundation will be moderating a session, “Beyond Amyloid and Tau: Emerging Solutions,” at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference, which will be held November 29th through December 2nd at the Hilton Union Square in San Francisco, California.

The rising investments in gene synthesis is among the chief factors that is expected to fuel the growth of the global gene synthesis market.

Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, announced, that following seven years of accelerated growth at Rentschler Biopharma under his leadership as Chief Executive Officer, Dr. Frank Mathias will return to the company’s Supervisory Board at the end of the fiscal year in March 2023.

An analysis by researchers at City of Hope found that cancer patients with privatized, cost-saving Medicare Advantage were more likely than those with traditional Medicare to go to hospitals with physicians less experienced at performing complicated surgeries, and that they were more likely to die within the first 30 days after the removal of their stomach, pancreas or liver.

Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.

Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that management will be participating in the following investor conferences.

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.

Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one new employee to purchase an aggregate of 20,000 ordinary shares under Avadel’s 2021 Inducement Plan.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2022 (“Q3 2022”) as compared to the three months ended September 30, 2021(“Q3 2021”).